Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00172120 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT00172120 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 91 participants.
The verdict
NCT00172120, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
TRES will evaluate the effects of continued ALX1-11 treatment on the safety and efficacy variables assessed in the OLE study for a maximum treatment duration of 36 months in OLES and TRES combined.
Interventions
- DRUG ALX1-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2005-01-10 |
| Est. Completion | 2006-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00172120
The ClinicalTrials.gov registry entry for NCT00172120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALX1-11 is the first listed.
NCT00172120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00172120 about?
NCT00172120 is a clinical study titled "Open Label Extension". TRES will evaluate the effects of continued ALX1-11 treatment on the safety and efficacy variables assessed in the OLE study for a maximum treatment duration of 36 months in OLES and TRES combined.
What is the current status of trial NCT00172120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2005-01-10. Estimated completion is 2006-10-27.
What interventions are being tested in trial NCT00172120?
The interventions under investigation include: ALX1-11 (DRUG).
Who is sponsoring clinical trial NCT00172120?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.